For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251117:nRSQ6870Ha&default-theme=true
RNS Number : 6870H CVS Group plc 17 November 2025
17 November 2025
CVS GROUP plc
("CVS" or the "Company" and, together with its subsidiaries, the "Group")
Transaction in own shares
CVS announces that on 14 November 2025 it purchased the following number of
its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg,
Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the
terms of the share buyback programme announced on 24 October 2025 (the "Share
Buyback Programme").
Date of purchase: 14/11/2025
Aggregate number of Ordinary Shares purchased: 26,396
Lowest price paid per share (GBp): 1,128.00
Highest price paid per share (GBp): 1,148.00
Volume weighted average price paid per share (GBp): 1,136.24
CVS intends to cancel all of the purchased Ordinary Shares.
Following settlement of the above purchases and cancellation of the Ordinary
Shares purchased, CVS will have 71,316,491 Ordinary Shares in issue and holds
no Ordinary Shares in treasury.
The total number of voting rights in CVS is therefore 71,316,491 and this
figure may be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, CVS under the Financial Conduct Authority's
Disclosure and Transparency Rules.
Since the commencement of the Share Buyback Programme, the Company has
repurchased 424,292 Ordinary Shares in aggregate at a weighted average price
of 1,244.89 pence per share.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market
Abuse Regulation), as it forms part of Retained EU Law as defined in the
European Union (Withdrawal) Act 2018, the table below contains detailed
information of the individual trades made by Berenberg as part of the Share
Buyback Programme.
Individual transactions:
Number of Transaction price (GBp share) Time of Transaction Trading Venue
Ordinary Shares purchased transaction (UK Time) reference number
215 1134 14/11/2025 08:00:40 1332909357140974 XLON
273 1130 14/11/2025 08:03:45 1332909357142614 XLON
86 1128 14/11/2025 08:08:32 1332909357144639 XLON
13 1128 14/11/2025 08:08:32 1332909357144640 XLON
85 1128 14/11/2025 08:08:42 1332909357144672 XLON
76 1128 14/11/2025 08:15:52 1332909357147470 XLON
444 1132 14/11/2025 08:26:10 1332909357149407 XLON
76 1132 14/11/2025 08:31:28 1332909357150332 XLON
376 1134 14/11/2025 08:44:55 1332909357153622 XLON
422 1134 14/11/2025 08:44:55 1332909357153623 XLON
80 1134 14/11/2025 08:45:38 1332909357153808 XLON
39 1132 14/11/2025 08:51:00 1332909357154736 XLON
805 1132 14/11/2025 08:51:00 1332909357154737 XLON
76 1132 14/11/2025 08:52:15 1332909357154866 XLON
743 1132 14/11/2025 09:01:35 1332909357156233 XLON
149 1132 14/11/2025 09:01:35 1332909357156234 XLON
275 1132 14/11/2025 09:09:23 1332909357157451 XLON
478 1132 14/11/2025 09:09:23 1332909357157452 XLON
1136 1136 14/11/2025 09:44:10 1332909357162081 XLON
712 1136 14/11/2025 09:44:10 1332909357162082 XLON
225 1136 14/11/2025 09:44:10 1332909357162083 XLON
136 1136 14/11/2025 09:59:59 1332909357163662 XLON
314 1134 14/11/2025 10:18:17 1332909357165692 XLON
198 1134 14/11/2025 10:18:17 1332909357165695 XLON
76 1132 14/11/2025 10:41:43 1332909357168657 XLON
348 1130 14/11/2025 11:00:12 1332909357170872 XLON
239 1130 14/11/2025 11:00:12 1332909357170873 XLON
952 1130 14/11/2025 11:21:51 1332909357173620 XLON
2 1130 14/11/2025 11:21:52 1332909357173629 XLON
658 1130 14/11/2025 11:42:02 1332909357175641 XLON
634 1130 14/11/2025 11:42:02 1332909357175642 XLON
17 1128 14/11/2025 11:42:19 1332909357175675 XLON
16 1128 14/11/2025 11:42:46 1332909357175729 XLON
608 1128 14/11/2025 11:47:09 1332909357176433 XLON
1212 1136 14/11/2025 12:53:43 1332909357183918 XLON
470 1136 14/11/2025 12:53:43 1332909357183920 XLON
252 1138 14/11/2025 12:58:49 1332909357184498 XLON
1300 1136 14/11/2025 13:10:47 1332909357185797 XLON
1308 1136 14/11/2025 13:10:47 1332909357185798 XLON
709 1138 14/11/2025 13:40:04 1332909357188584 XLON
1320 1140 14/11/2025 13:49:27 1332909357189886 XLON
968 1140 14/11/2025 13:49:29 1332909357189898 XLON
200 1148 14/11/2025 13:52:58 1332909357190417 XLON
982 1146 14/11/2025 13:54:32 1332909357190590 XLON
275 1146 14/11/2025 13:54:33 1332909357190591 XLON
76 1144 14/11/2025 13:57:33 1332909357190905 XLON
234 1144 14/11/2025 13:57:33 1332909357190906 XLON
341 1138 14/11/2025 14:10:15 1332909357192775 XLON
197 1138 14/11/2025 14:10:15 1332909357192777 XLON
268 1136 14/11/2025 14:26:40 1332909357194556 XLON
306 1136 14/11/2025 14:30:55 1332909357195586 XLON
100 1136 14/11/2025 14:30:55 1332909357195608 XLON
501 1136 14/11/2025 14:30:55 1332909357195609 XLON
1341 1138 14/11/2025 14:39:43 1332909357197915 XLON
622 1138 14/11/2025 14:39:43 1332909357197916 XLON
100 1138 14/11/2025 14:39:43 1332909357197917 XLON
68 1138 14/11/2025 14:39:43 1332909357197918 XLON
24 1138 14/11/2025 14:39:43 1332909357197919 XLON
784 1138 14/11/2025 14:40:04 1332909357198014 XLON
60 1138 14/11/2025 14:40:04 1332909357198015 XLON
360 1142 14/11/2025 15:07:18 1332909357204815 XLON
556 1144 14/11/2025 15:08:40 1332909357205115 XLON
480 1148 14/11/2025 15:18:38 1332909357207301 XLON
Contacts
CVS Group plc
via Camarco
Richard Fairman, CEO
Robin Alfonso, CFO
Paul Higgs, Chief Veterinary Officer
Charlotte Page, Head of Investor Relations
Peel Hunt LLP (Nominated Adviser & Joint
Broker)
+44 (0)20 7418 8900
Christopher Golden / James Steel / Andrew Clark
Berenberg (Joint
Broker) +44
(0)20 3207 7800
Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing
Camarco (Financial
PR)
cvsg@camarco.co.uk
Ginny Pulbrook
+44 (0)7961 315 138
Letaba Rimell
Tilly Butcher
About CVS Group plc (www.cvsukltd.co.uk)
CVS Group is an AIM-listed provider of veterinary services with operations in
the UK and Australia. CVS is focused on providing high-quality clinical
services to its clients and their animals, with outstanding and dedicated
clinical teams and support colleagues at the core of its strategy.
The Group now operates c.470 veterinary practices across its two territories,
including specialist referral hospitals and dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties) and an online retail
business ("Animed Direct").
The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and
c.3,300 nurses.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END POSGPGGPGUPAGBC
Copyright 2019 Regulatory News Service, all rights reserved